Literature DB >> 9797251

Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains.

D Deidda1, G Lampis, R Fioravanti, M Biava, G C Porretta, S Zanetti, R Pompei.   

Abstract

The pyrrole derivative BM212 [1, 5-diaryl-2-methyl-3-(4-methylpiperazin-1-yl)methyl-pyrrole] was shown to possess strong inhibitory activity against both Mycobacterium tuberculosis and some nontuberculosis mycobacteria. BM212 was inhibitory to drug-resistant mycobacteria and also exerted bactericidal activity against intracellular bacilli residing in the U937 human histiocytic lymphoma cell line.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9797251      PMCID： PMC105991     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  The combined effect of rifampin and pyrazinamide within the human macrophage.

Authors:  J A Sbarbaro; M D Iseman; A J Crowle
Journal:  Am Rev Respir Dis       Date:  1992-12

2.  The global tuberculosis situation and the new control strategy of the World Health Organization.

Authors:  A Kochi
Journal:  Tubercle       Date:  1991-03

3.  Multidrug-resistant tuberculosis.

Authors:  S W Dooley; W R Jarvis; W J Martone; D E Snider
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

4.  MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

5.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

6.  Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli.

Authors:  M A Fischl; G L Daikos; R B Uttamchandani; R B Poblete; J N Moreno; R R Reyes; A M Boota; L M Thompson; T J Cleary; S A Oldham
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

7.  Synthesis and microbiological evaluations of (N-heteroaryl) arylmethanamines and their Schiff bases.

Authors:  R Fioravanti; M Biava; S Donnarumma; G C Porretta; N Simonetti; A Villa; A Porta-Puglia; D Deidda; C Maulla; R Pompei
Journal:  Farmaco       Date:  1996-10

8.  Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers.

Authors:  M L Pearson; J A Jereb; T R Frieden; J T Crawford; B J Davis; S W Dooley; W R Jarvis
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

Review 9.  Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome.

Authors:  F M Collins
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

10.  Studies on anti-Candida agents with a pyrrole moiety. Synthesis and microbiological activity of some [(1-alkyl),(1-aryl) and (1-benzyl)-5-aryl-3-carboxamido-2-methyl]pyrrole derivatives.

Authors:  M Scalzo; M Biava; F Cerreto; A Villa
Journal:  Farmaco       Date:  1992 Jul-Aug
View more
  19 in total

1.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance.

Authors:  Hongtai Zhang; Dongfang Li; Lili Zhao; Joy Fleming; Nan Lin; Ting Wang; Zhangyi Liu; Chuanyou Li; Nicholas Galwey; Jiaoyu Deng; Ying Zhou; Yuanfang Zhu; Yunrong Gao; Tong Wang; Shihua Wang; Yufen Huang; Ming Wang; Qiu Zhong; Lin Zhou; Tao Chen; Jie Zhou; Ruifu Yang; Guofeng Zhu; Haiying Hang; Jia Zhang; Fabin Li; Kanglin Wan; Jun Wang; Xian-En Zhang; Lijun Bi
Journal:  Nat Genet       Date:  2013-09-01       Impact factor: 38.330

Review 2.  The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: Part II: scientific advances that may provide solutions.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

Review 3.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

Review 4.  Current development and future prospects in chemotherapy of tuberculosis.

Authors:  Eric L Nuermberger; Melvin K Spigelman; Wing Wai Yew
Journal:  Respirology       Date:  2010-06-04       Impact factor: 6.424

Review 5.  New drugs and regimens for treatment of TB.

Authors:  Eric Leibert; William N Rom
Journal:  Expert Rev Anti Infect Ther       Date:  2010-07       Impact factor: 5.091

6.  HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter.

Authors:  Huiqing Zheng; John T Williams; Garry B Coulson; Elizabeth R Haiderer; Robert B Abramovitch
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 7.  Drugs in development for tuberculosis.

Authors:  Ann M Ginsberg
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

8.  Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target.

Authors:  Cedric P Owens; Nicholas Chim; Celia W Goulding
Journal:  Future Med Chem       Date:  2013-08       Impact factor: 3.808

Review 9.  New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.

Authors:  E Jeffrey North; Mary Jackson; Richard E Lee
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

10.  Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Authors:  Giovanna Poce; Sara Consalvi; Giulia Venditti; Salvatore Alfonso; Nicoletta Desideri; Raquel Fernandez-Menendez; Robert H Bates; Lluis Ballell; David Barros Aguirre; Joaquin Rullas; Alessandro De Logu; Michelle Gardner; Thomas R Ioerger; Eric J Rubin; Mariangela Biava
Journal:  ACS Med Chem Lett       Date:  2019-09-18       Impact factor: 4.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.